Case Studies

Jannini, Emmanuele A.; Porst, Hartmut

doi:10.1111/j.1743-6109.2011.02457.x

Cited by 2 publications

(1 citation statement)

References 15 publications

(29 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Prior to the use of dapoxetine, there were no approved pharmacological therapies for PE; therefore, treatment involved the off-label use of selective serotonin reuptake inhibitors (SSRIs) and topical agents, alone and in combination with other drugs 89101112…”

Section: Introductionmentioning

confidence: 99%

Comparison of paroxetine and dapoxetine, a novel selective serotonin reuptake inhibitor in the treatment of premature ejaculation

et al. 2014

View full text Add to dashboard Cite

Dapoxetine hydrochloride is a selective serotonin reuptake inhibitor and the first drug approved for the on-demand treatment of premature ejaculation (PE). Our objective in this study was to characterize the efficacy of on-demand dapoxetine (30 and 60 mg) and daily paroxetine (20 mg) usage in treating PE. We conducted a 1 month study involving a total of 150 patients. Patients were divided into three groups of 50. Group 1 were treated with on-demand dapoxetine (30 mg), Group 2 with on-demand dapoxetine (60 mg) and Group 3 with daily paroxetine (20 mg). Our outcome measurement was increased from baseline intravaginal ejaculatory latency time (IELT) after treatment. The IELT increased from baseline to posttreatment by 117%, 117% and 170% in the paroxetine group (P < 0.01), 30 mg dapoxetine group (P < 0.01) and 60 mg dapoxetine group (P < 0.01), respectively. The increase from baseline IELT were similar for the 30 mg dapoxetine and paroxetine groups (P > 0.05), while the 60 mg dapoxetine group had a larger posttreatment IELT increase compared with the 30 mg dapoxetine (P < 0.05) and paroxetine (P < 0.01) groups. Dapoxetine (60 mg) 1–3 h before planned intercourse is a very effective treatment modality for PE. However, an on-demand dose of 30 mg dapoxetine is no more effective than the currently prescribed paroxetine treatment.

show abstract

Section: Introductionmentioning

confidence: 99%

Comparison of paroxetine and dapoxetine, a novel selective serotonin reuptake inhibitor in the treatment of premature ejaculation

et al. 2014

View full text Add to dashboard Cite

show abstract

Non‐pharmacological approaches for treatment of premature ejaculation: a systematic review

Pizzol¹,

Sánchez

Ilie

et al. 2023

Trends Urol & Men's Health

View full text Add to dashboard Cite

Premature ejaculation is a common male condition worldwide with prevalence estimates varying from 30% to 85%. Owing to the lack of a clear definition and a clear understanding of the potentially multifactorial pathophysiology, treatment remains challenging. The aim of this systematic review was to evaluate the non‐pharmacological treatment modalities for PE to inform clinical practice and patients.

show abstract

Case Studies

Cited by 2 publications

References 15 publications

Comparison of paroxetine and dapoxetine, a novel selective serotonin reuptake inhibitor in the treatment of premature ejaculation

Comparison of paroxetine and dapoxetine, a novel selective serotonin reuptake inhibitor in the treatment of premature ejaculation

Non‐pharmacological approaches for treatment of premature ejaculation: a systematic review

Contact Info

Product

Resources

About